Oncologists of today must adapt to rapid changes in practice. The promising results of immunotherapies in oncology are generating increasing interest from the oncology community and have the potential to become the standard of care.
This year sees the launch of the ESMO Immuno Oncology Congress, the new highly-focused meeting devoted entirely to the development and use of immunotherapies against cancer.
The creation of the ESMO Immuno Oncology Congress reflects ESMO’s commitment to providing oncologists who need to learn how to apply the latest standards of care in the immunotherapy of cancer with a comprehensive update in an environment rich with highly specialised professionals.
The Cancer Research Institute's Chief Medical Officer Aiman Shalabi, Pharm.D., MBA, BCOP, speaks at the pre-conference press conference on December 7, 2017 at 12:15 pm CET. He also presents in the session "The role of philanthropy in supporting cancer immunotherapy" on December 9, 2017 at 8:00 am CET.
